Cargando…

Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases

PURPOSE: Switch from zoledronic acid (ZA) to denosumab may increase the risk of medication-related osteonecrosis of the jaw (MRONJ) owing to the additive effect of denosumab on the jawbone and residual ZA activities. We evaluated the risk of developing MRONJ in patients who received ZA, denosumab, o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ikesue, Hiroaki, Doi, Kohei, Morimoto, Mayu, Hirabatake, Masaki, Muroi, Nobuyuki, Yamamoto, Shinsuke, Takenobu, Toshihiko, Hashida, Tohru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8110486/ https://www.ncbi.nlm.nih.gov/pubmed/33791853 http://dx.doi.org/10.1007/s00280-021-04262-w

Ejemplares similares

Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score–matched analysis
por: Ikesue, Hiroaki, et al.
Publicado: (2021)

Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases
por: Ikesue, Hiroaki, et al.
Publicado: (2021)

Osteonecrosis of the Jaw Caused by Denosumab in Treatment-Naïve and Pre-Treatment with Zoledronic Acid Groups: A Time-to-Onset Study Using the Japanese Adverse Drug Event Report (JADER) Database
por: Hasegawa, Shiori, et al.
Publicado: (2022)

Risk factors of proteinuria and potentially protective effect of renin–angiotensin system inhibitors in patients with renal cell carcinoma receiving axitinib
por: Ikesue, Hiroaki, et al.
Publicado: (2022)

Denosumab and osteonecrosis of the jaw
por: Bower, Robert
Publicado: (2019)

Osteonecrosis of the jaw and denosumab
por: Goss, Alastair N
Publicado: (2022)

Denosumab/ibandronic acid/zoledronic acid: Medication-related osteonecrosis of jaw: case report
Publicado: (2021)

Pharmacist-Urologist Collaborative Management Improves Clinical Outcomes in Patients With Castration-Resistant Prostate Cancer Receiving Enzalutamide
por: Hirabatake, Masaki, et al.
Publicado: (2022)

Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma
por: Yamaoka, Kenta, et al.
Publicado: (2023)

Pharmacokinetics of Temozolomide in a Patient With Glioblastoma Undergoing Hemodialysis: A Short Communication
por: Tanaka, Fumiaki, et al.
Publicado: (2023)

Evaluation of the usefulness of protocol‐based pharmacist‐facilitated laboratory monitoring to ensure the safety of immune checkpoint inhibitors in patients with lung cancer
por: Ikesue, Hiroaki, et al.
Publicado: (2020)

Population Pharmacokinetics of Nivolumab in Japanese Patients with Nonsmall Cell Lung Cancer
por: Tohi, Makiko, et al.
Publicado: (2023)

Evaluating the safety and efficiency of robotic dispensing systems
por: Takase, Tomoki, et al.
Publicado: (2022)

Denosumab Related Osteonecrosis of Jaw: a Case Report
por: de Sales Lima, Marco Vinícius, et al.
Publicado: (2018)

Safety and efficacy evaluation of low-dose trimethoprim-sulfamethoxazole for prophylaxis of Pneumocystis pneumonia in HIV uninfected patients undergoing hemodialysis: a retrospective observational study
por: Yamashita, Kanae, et al.
Publicado: (2021)

Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology
por: Fusco, Vittorio, et al.
Publicado: (2018)

Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis
por: Limones, Alvaro, et al.
Publicado: (2020)

Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab
por: Neuprez, A., et al.
Publicado: (2013)

Zoledronate‐Associated Osteonecrosis of the Jaw in a Dog with Appendicular Osteosarcoma
por: Lundberg, A.P., et al.
Publicado: (2016)

Dental extraction following zoledronate, induces osteonecrosis in rat´s jaw
por: Vidal-Gutiérrez, Ximena, et al.
Publicado: (2017)

Medication-Related Osteonecrosis of the Jaws Initiated by Zoledronic Acid and Potential Pathophysiology
por: Alsalih, Aya, et al.
Publicado: (2021)

Reply to Comment—Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published in Lancet Oncology
por: Raje, Noopur, et al.
Publicado: (2019)

Denosumab-related osteonecrosis of the jaw in a patient with bone metastases of prostate cancer: A case report and literature review
por: Yoshimura, Hitoshi, et al.
Publicado: (2017)

A Model for Osteonecrosis of the Jaw with Zoledronate Treatment following Repeated Major Trauma
por: Howie, R. Nicole, et al.
Publicado: (2015)

Effect of the number of dose adjustment factors on bleeding risk in patients receiving 30 mg/day edoxaban
por: Takase, Tomoki, et al.
Publicado: (2019)

Association between 25-hydroxyvitamin D levels and COVID-19 severity
por: Takase, Tomoki, et al.
Publicado: (2022)

Polypharmacy-associated potential contraindications of drug prescriptions in patients with primary angle closure disease in a real-world setting
por: Tanaka, Fumiaki, et al.
Publicado: (2021)

Population pharmacokinetics and exposure–clinical outcome relationship of remdesivir major metabolite GS‐441524 in patients with moderate and severe COVID‐19
por: Tamura, Ryo, et al.
Publicado: (2023)

A Retrospective Observational Study of Risk Factors for Denosumab-Related Osteonecrosis of the Jaw in Patients with Bone Metastases from Solid Cancers
por: Okuma, Satoe, et al.
Publicado: (2020)

384. Denosumab-Related Osteonecrosis of the Jaw: an Emergent and Potentially Complex Bone and Joint Infection
por: Bricca, Romain, et al.
Publicado: (2019)

Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab
por: Wick, Alexander, et al.
Publicado: (2021)

Long-term use of denosumab and its association with skeletal-related events and osteonecrosis of the jaw
por: Fu, Pei-An, et al.
Publicado: (2023)

Platelet-Rich Plasma in Treatment of Zoledronic Acid-Induced Bisphosphonate-related Osteonecrosis of the Jaws
por: Sarkarat, Farzin, et al.
Publicado: (2014)

Geranylgeraniol Restores Zoledronic Acid-Induced Efferocytosis Inhibition in Bisphosphonate-Related Osteonecrosis of the Jaw
por: Chen, Xin, et al.
Publicado: (2021)

A real‐world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with Denosumab
por: Bracchi, Paola, et al.
Publicado: (2023)

Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID‐19
por: Irie, Kei, et al.
Publicado: (2020)

Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab) - Review
por: de Oliveira, Camila-Carvalho, et al.
Publicado: (2016)

Osteonecrosis of the jaws associated with denosumab: Study of clinical and radiographic characteristics in a series of clinical cases
por: Tofé, Victoria I., et al.
Publicado: (2020)

An Approach for the Prevention, Diagnosis, and Treatment of Jaw Osteonecrosis: Report of a Case Associated with Zoledronic Acid
por: de Alexandria Santos, Danila S., et al.
Publicado: (2020)

Denosumab Related Osteonecrosis of the Jaw with Spontaneous Necrosis of the Soft Palate: Report of a Life Threatening Case
por: Qaisi, Mohammed, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ft5kae657d9bughttaudhpuq9r